-
Product Insights
NewLikelihood of Approval Analysis for Generalized Anxiety Disorder (GAD)
Overview How likely is it that the drugs in Generalized Anxiety Disorder (GAD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Generalized Anxiety Disorder (GAD) Overview Generalized anxiety disorder is a...
-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s AAV-GAD
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's AAV-GAD report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zuranolone in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zuranolone in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zuranolone in Generalized Anxiety Disorder (GAD) Drug Details: Zuranolone...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Deuterated Etifoxine in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deuterated Etifoxine in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deuterated Etifoxine in Generalized Anxiety Disorder (GAD) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-5279 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-5279 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-5279 in Generalized Anxiety Disorder (GAD) Drug Details: JNJ-5279 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ulotaront Hydrochloride in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulotaront Hydrochloride in Generalized Anxiety Disorder (GAD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPL-028 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-028 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SPL-028 in Generalized Anxiety Disorder (GAD) Drug Details: SPL-028 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lysergic Acid Diethylamide in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lysergic Acid Diethylamide in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lysergic Acid Diethylamide in Generalized Anxiety Disorder...
-
Product Insights
Generalized Anxiety Disorder (GAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Generalized Anxiety Disorder (GAD) - Drugs In Development, 2023’, provides an overview of the Generalized Anxiety Disorder (GAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Generalized Anxiety Disorder (GAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...